Pacira BioSciences (PCRX) Convertible Debt (2013 - 2025)

Pacira BioSciences' Convertible Debt history runs 13 years deep, the most recent figure standing at $280.3 million for Q2 2025.

• On a quarterly basis, Convertible Debt fell 41.56% year-over-year to $280.3 million in Q2 2025; TTM through Jun 2025 was $280.3 million, a 41.56% decrease from a year earlier, with the FY2024 full-year figure at $279.3 million, down 29.92% from the prior year.
• Convertible Debt steadied at $280.3 million in Q2 2025 per PCRX's latest filing, from $279.8 million in the prior quarter.
• Across five years, Convertible Debt topped out at $479.5 million in Q2 2024 and bottomed at $278.9 million in Q3 2024.
• The 5-year median for Convertible Debt is $397.7 million (2023), against an average of $362.0 million.
• Across the five-year window, Convertible Debt gained 26.97% in 2022 and slumped 41.56% in 2025, its largest moves.
• Year by year, Convertible Debt stood at $339.3 million in 2021, then advanced by 19.31% to $404.8 million in 2022, then fell by 1.53% to $398.6 million in 2023, then retreated by 29.92% to $279.3 million in 2024, then increased by 0.33% to $280.3 million in 2025.
• Per Business Quant, the three latest PCRX Convertible Debt figures stand at $280.3 million (Q2 2025), $279.8 million (Q1 2025), and $279.3 million (Q4 2024).